Combining CTLA-4 and angiopoietin-2 blockade in patients with advanced melanoma: a phase I trial
Combining CTLA-4 and angiopoietin-2 blockade in patients with advanced melanoma: a phase I trial
About this item
Full title
Author / Creator
Publisher
England: BMJ Publishing Group Ltd
Journal title
Language
English
Formats
Publication information
Publisher
England: BMJ Publishing Group Ltd
Subjects
More information
Scope and Contents
Contents
BackgroundAngiogenic factors promote the growth of tumor vasculature, modulate lymphocyte trafficking into tumors, and inhibit maturation of dendritic cells. We hypothesized that MEDI3617, a human IgG1 kappa monoclonal antibody directed against human angiopoietin-2, in combination with tremelimumab (treme), an IgG2 monoclonal antibody blocking cyto...
Alternative Titles
Full title
Combining CTLA-4 and angiopoietin-2 blockade in patients with advanced melanoma: a phase I trial
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_209a1d9fbce1433f83f364f311d116e0
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_209a1d9fbce1433f83f364f311d116e0
Other Identifiers
ISSN
2051-1426
E-ISSN
2051-1426
DOI
10.1136/jitc-2021-003318
